MedTrace Logo

A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)

NCT04220411 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-12-11

Study results available
· View outcomes & findings →

Summary

This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Health Subjects, and Subjects with Mild to Moderate Atopic Dermatitis.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

AR100DP1

topical ointment

Sponsors & Collaborators

  • Arjil Pharmaceuticals LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2021-12-29
Completion
2022-06-13
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04220411 on ClinicalTrials.gov